Overview

i-Cord Cord Blood Bank

Bio
Insurance

iCord is the culmination of CHA Medical Group’s extensive expertise in stem cell research and development

What is Cord Blood?
Cord blood refers to the blood found in a newborn’s umbilical cord, rich in hematopoietic stem cells (which create blood cells) and mesenchymal stem cells (which form cartilage, bone, and muscle).
These cells have immense regenerative potential, making cord blood a highly valuable resource
for the future of medical treatments.
Hematopoietic Stem Cells
  • ”Mother” cells that produce blood cells such as white blood cells, red blood cells, and platelets, including immune cells that help maintain a healthy immune system through its blood-forming ability
Mesenchymal Stem Cells
  • A type of stem cells with excellent self-renewal and multipotent differentiation capabilities, capable of differentiating into cells of bone, cartilage, muscle, bone marrow, and various organs
Immunocyte (Immune Cells)
  • Cells that defend themselves against invading pathogens or viruses and destroy cancer cells
What Sets iCord Apart?
Unrivaled Technology
  • CHA Biotech leads future medicine, focusing on stem cell research and treatment development for intractable diseases. CHA Biotech offers a comprehensive solution from stem cell production to treatment by continuously developing core technologies for embryonic and adult stem cells. This expertise has enabled iCord to become a leader in the cord blood storage business, a crucial element of regenerative medicine.
Financial Stability
  • iCord boasts the largest total assets among family cord blood banks in Korea, with CHA Biotech’s total assets reaching KRW 2.07 trillion (over four times larger than its competitors'), according to the 2024 3Q business report filed with the Financial Supervisory Service.
One-Stop Bio-Medical Complex
  • iCord offers a seamless system that spans the entire process from cord blood storage to transplantation and treatment.
Future Value of Cord Blood
Diseases Treatable with Family Allogeneic Hematopoietic Stem Cell Transplantation
Malignant Tumors Leukemia (high-risk and relapsed acute lymphoblastic leukemia, high-risk and relapsed acute myeloid leukemia, relapsed chronic myeloid leukemia, juvenile myelomonocytic leukemia, chronic lymphocytic leukemia), Hodgkin’s disease (advanced stage or relapsed), non-Hodgkin lymphoma (relapsed).
Blood Disorders Myelodysplastic syndrome, refractory anemia, other myeloproliferative disorders, multiple myeloma, Langerhans cell histiocytosis (relapsed), hemophagocytic lymphohistiocytosis, severe aplastic anemia, congenital aplastic anemia, Fanconi anemia.
Other Conditions Immune deficiency diseases, genetic metabolic disorders, hemoglobinopathies, and other conditions that can be treated with allogeneic hematopoietic stem cell transplants.
Diseases Treatable with Autologous Hematopoietic Stem Cell Transplantation

Hodgkin’s disease (advanced stage or relapsed), relapsed non-Hodgkin lymphoma, multiple myeloma, acquired severe aplastic anemia (when no allogeneic donor is available), and advanced-stage neuroblastoma

Diseases in Clinical Trials for Autologous and Family Cord Blood :
Cerebral palsy, developmental disorders, type 1 diabetes, and autism

As medical technology continues to advance, autologous and family cord blood may be used for stem cell and immune cell therapies for targeted diseases, pending further validation through clinical trials.

(Source: Ministry of Health and Welfare, Bioethics Policy Division, “Promotion and Terms Guidelines” as of June 2020)